Gulf Scientific Corporation is honored to announce its collaboration with Al Jalila Children’s Specialty Hospital and the launch of a pharmacogenomic pilot study to assess and correlate therapeutic drug responses with pharmacogenetic (PGx) information.

On behalf of Gulf Scientific Corporation, Manaf Afyouni, Managing Director, wishes to extend his gratitude to Dr. Ahmad Abou Tayoun, Director of the Genomics Center of Excellence and his esteemed research team at Al Jalila Hospital, as well as Dr. Omar Alsokhni, Director of the Pharmacy Department for conducting this valuable study that will improve the pediatric patients care through providing better clinical outcomes, in terms of both efficacy and safety.

As part of Gulf Scientific Corporation’s commitment to provide innovative solutions to serve the scientific community and improve patients’ quality of life, GSC provided PharmacoScan solution, the industry’s broadest content genetic analysis system, specifically designed in collaboration with experts in the field of Pharmacogenomics at Thermo Fisher Scientific in the USA, to provide insights and understand how genetic variations affect drug absorption.

Gulf Scientific Corporation and ThermoFisher Scientific have demonstrated over the years their unwavering commitment to the establishment and development of the scientific community across the Gulf Cooperation Council.

To find out more information about the study, click here.

#aljalilachildrens #ajch #thermofisherscientific #pharmacogenomics #PGx #PharmacoScan #GeneTitan #mygulfscientific #gulfscientificcorporation